



Canadian Journal of Physiology and Pharmacology

Anticancer Activity of Sinapic Acid by Inducing Apoptosis in HT-29 Human Colon Cancer Cell Line

Journal:	<i>Canadian Journal of Physiology and Pharmacology</i>
Manuscript ID	cjpp-2022-0523
Manuscript Type:	Article
Date Submitted by the Author:	11-Nov-2022
Complete List of Authors:	Tastemur, Seyma; Sivas Cumhuriyet University, Department of Internal Medicine Hacisüleyman, Levent ; Sivas Cumhuriyet University Karatas, Ozhan; Sivas Cumhuriyet University, Department of Veterinary Pathology yulak, Fatih; Sivas Cumhuriyet University Ataseven, Hilmi; Sivas Cumhuriyet University, Department of Internal Medicine
Is the invited manuscript for consideration in a Special Issue:	Not applicable (regular submission)
Keyword:	Sinapic acid, Colorectal Cancer, HT-29 Cell Line, Antiproliferative Effect

SCHOLARONE™
Manuscripts

1 **Anticancer Activity of Sinapic Acid by Inducing Apoptosis in HT-29**

2 **Human Colon Cancer Cell Line**

3 Şeyma Taştumur¹, Levent Hacısüleyman², Özhan Karataş³, Fatih Yulak⁴, Hilmi Ataseven⁵.

4 ¹ Department of Internal Medicine, Sivas Numune Hospital, Sivas, Turkey.

5 ² Department of Pharmacology, School of Pharmacy, Cumhuriyet University, Sivas, Turkey.

6 ³ Department of Veterinary Pathology, School of Veterinary Medicine, Cumhuriyet University, Sivas, Turkey.

7 ⁴ Department of Physiology, School of Medicine, Cumhuriyet University, Sivas, Turkey.

8 ⁵ Department of Internal Medicine, Discipline of Gastroenterology, School of Medicine, Cumhuriyet University,
9 Sivas, Turkey.

10 *Corresponding author:

11 Name: Levent Hacısüleyman

12 Affiliation: Department of Pharmacology, School of Pharmacy, Cumhuriyet University, Sivas, Turkey

13 E-mail: maan.pharm@hotmail.com Tel: 00905364664498

14 **Abstract**

15 **Background:** Colorectal cancer is the third most lethal and fourth most commonly diagnosed
16 cancer worldwide. Sinapic acid, a derivative of hydroxycinnamic acid, is a promising
17 phytochemical exhibiting numerous pharmacological activities in various systems. It is a
18 substantial chain-breaking antioxidant that operates as a radical scavenger. The aim of this research
19 was to investigate the antiproliferative effect of sinapic acid on the HT-29 cell line, besides the
20 mechanisms underlying this activity.

21 **Materials and Methods:** The effect of sinapic acid on the viability of HT-29 cell line was
22 investigated using XTT assay. the levels of BCL-2, cleaved caspase 3, BAX, cleaved PARP and

23 8-oxo-dG were measured using ELISA. Gamma-H2AX and cytochrome C expression was
24 assessed semi-quantitatively using immunofluorescence staining.

25 **Results:** Sinapic acid at 200 μM and higher doses produced a significant antiproliferative effect
26 on HT-29 cells. The IC50 value was found to be 317.5 μM for 24 hours. Sinapic acid (317.5 μM)
27 significantly elevated cleaved caspase 3, BAX, cleaved PARP and 8-oxo-dG levels. the levels of
28 γ -H2AX foci are significantly higher while the levels of cytochrome-C are lower in sinapic acid
29 treated HT-29 cells.

30 **Conclusion:** These results indicate that sinapic acid has an antiproliferative, apoptotic and
31 genotoxic effect on colon cancer cells.

32 **Keywords:** Sinapic acid, Colorectal Cancer, HT-29 Cell Line, Antiproliferative Effect.

33 **Introduction**

34 GLOBOCAN 2018 data indicates that colorectal cancer is the third most lethal and fourth most
35 commonly diagnosed cancer worldwide (1). Colon cancer affects nearly 150,000 Americans
36 yearly, almost a third of whom die, (2), about 250,000 in Europe (3) and almost 1 million people
37 all around the world (4). The interactions between genes and environment together with the
38 excessive dietary fat intake play a crucial role in the etiology of colon cancer (5). Activated
39 oncogenes and inactivated tumor suppressor genes can lead to hyperplasia and provide protection
40 to cancer cells against apoptosis, giving rise to a dysfunction in cell processes (DNA replication,
41 cell cycles, dysplasia, and immune-cell interactions) (6,7). knockout trials in mice have
42 demonstrated that low dose (<10 Gy) gamma radiation-induced apoptosis, limited to epithelial
43 cells, is mediated by BAX and p53 and is antagonized by bcl-2 and bcl-w (8-11). It has been
44 demonstrated that food components known to inhibit the development of colon cancer enhance

45 apoptosis subsequent to DNA damage and this might represent a considerable mechanism of
46 cancer prevention (12). Colon cancer is linked to pathological outcomes of constant oxidative
47 stress and lipid peroxidation. Unsaturated lipids are vulnerable to oxidation and the metabolites of
48 lipid peroxidation produce the mutagenesis promoting exocyclic DNA adducts (13).

49 HT-29 is a human colon cancer cell line used widely in biological and cancer research (14). HT-
50 29 cells were initially obtained from a 44-year-old Caucasian female with colorectal
51 adenocarcinoma in 1964, HT-29 cells form a tight monolayer while showing resemblance to
52 enterocytes from the small intestines. HT-29 cells overexpress a mutated p53 tumor antigen
53 (having a histidine replacing an arginine due to a mutation at position 273 in p53 gene) (15).

54 The conventional treatments for colon cancer include surgery, radiotherapy, chemotherapy.
55 Furthermore, current approaches also involve targeted therapies mainly for advanced stages of
56 colon cancer such as immunotherapy, gene therapy, cancer vaccines and cell therapy (16).

57 Chemotherapy-related toxicities and severe side effects such as diarrhea, provide a motivation for
58 persistent research aimed at finding effective phytochemicals that can reduce these risks and also
59 increase survival rates in metastatic colon cancer.

60 The uses of medicinal herbs and nutraceuticals have been steadily risen worldwide as their
61 effectiveness has been proven besides being safer compared to synthetic drugs (17). Phenolic acids
62 are renowned as reactive chemicals that have an effect on biological systems. They have got a lot
63 of attention in the fields of pharmaceutical and medical research because they appear to play a role
64 in the prevention of many diseases and involved in bioactivities applicable to human health.
65 Phenolic acids exist in almost all edible plants, and the daily dietary consumption by humans is
66 informed to be about 200mg (18, 19). Hydroxycinnamic acids form a main class of phenolic acids

67 found in the plant kingdom. Caffeic acid, ferulic acid, sinapic acid and p-coumaric acid are the
68 most common hydroxycinnamic acids (20). Sinapic acid (SA) is
69 3,5-dimethoxy-4-hydroxycinnamic acid (Figure 1) (21). Some of the sinapic acid-rich sources are
70 rice, wheat, oil, spices, vegetables, seeds, cereals, citrus fruits, and vinegar. Furthermore, SA has
71 been informed to be a main active constituent of Chinese traditional medicines (22). Sinapic acid
72 exhibits numerous pharmacological activities in various systems. Several in-vivo and in-vitro
73 researches have been carried out to demonstrate the pharmacological features such as antioxidant,
74 anticancer, analgesic, anti-inflammatory, and antimicrobial of SA and to clarify the mechanism of
75 action of this compound (23). SA is considered to be a substantial chain-breaking antioxidant that
76 fruitfully operates as a radical scavenger (24). This antioxidant activity is associated with its ability
77 to donate hydrogen atoms and the feature to stabilize the resulting phenoxy radicals via the
78 conjugated system (25).

79 The aim of this research was to investigate the antiproliferative effect of sinapic acid on the HT-
80 29 cell line, besides the mechanisms underlying this activity.

81 **Materials and methods**

82 *Cell culture and cell lines*

83 Colon adenocarcinoma cell line HT-29 was purchased from American Type Culture Collection.
84 The cells were grown in Dulbecco's modified Eagle's medium (Sigma-Aldrich) supplemented
85 with 10% fetal bovine serum (Sigma-Aldrich), 1% antibiotic mixtures of penicillin and
86 streptomycin at 37°C in a 5% CO₂ atmosphere in a humidified incubator. Before the procedure,
87 sinapic acid (Sigma-Aldrich) was dissolved in dimethyl sulfoxide (DMSO) and diluted in the
88 culture medium to a final DMSO concentration of less than 0.1%.

89 ***Cell viability test***

90 Using XTT test assay (Roche Diagnostic, MA, USA), the effect of SA on the viability of HT-29
91 cell line was investigated. These cells were cultured at a concentration of 1×10^4 cells per well and
92 incubated overnight before the addition of SA. After that the different concentrations (800, 400,
93 200 and 100 μM) of SA were applied to cells for 24 h. Untreated cells were used as a control. After
94 incubation, 50 μL of XTT mixture was added to each well. After 4-hour incubation, the cells were
95 shaken and the absorbance was measured using a microplate reader (Thermo Fisher Scientific,
96 Altrincham, United Kingdom) at 450 nm. Cell viability was evaluated as a percentage of live cells
97 versus control cells after each experiment was performed three times [26,27].

98 ***The measurement of BCL-2, cleaved caspase 3, BAX, cleaved PARP and 8-oxo-dG levels***

99 The human ELISA kits of BCL-2 (BT Lab, catalog #E1832HU), cleaved caspase 3 (BT Lab,
100 catalog # E6970HU), Bax (BT Lab, catalog #E1825HU), cleaved PARP (BT Lab, catalog
101 #E6971HU) and 8-hydroxy-desoxyguanosine (8-oxo-dG) (BT Lab, catalog #E1436HU) were used
102 to assess the levels of BCL-2, cleaved caspase 3, BAX, cleaved PARP and 8-oxo-dG in synaptic
103 acid-treated and untreated HT-29 cells. HT-29 cells were cultivated into a 6-well plate and treated
104 with 317.5 μM synaptic acid for 24 hours. HT-29 cells that had been treated with synaptic acid and
105 those that had not were gathered and diluted in PBS. Then they were frozen and thawed three
106 times. Following that, the quantities of BCL-2, cleaved caspase 3, BAX, cleaved PARP and 8-
107 oxo-dG in cell lysates were assessed following the manufacturer's instructions. Bradford protein
108 assay kit (Merck Millipore, Darmstadt, Germany) was used to calculate the total protein quantities
109 in both experimental and control HT-29 cells (28).

110 ***Immunofluorescence staining***

111 Cells were fixed with methanol for 5 minutes at -20°C and washed with PBS. They were then
112 incubated with PBS containing 0.1% Triton X-100 for 15 minutes at room temperature. After
113 washing, they were incubated with PBS containing 2% BSA for 60 minutes at room temperature.
114 After rewashing, they were incubated overnight with monoclonal anti-gamma H2AX (Abcam,
115 Catalog no. ab26350) and monoclonal anti-Cytochrome C (Abcam, Catalog no. ab110325)
116 primary antibodies at a dilution ratio of 1/300 at +4°C. Cells were washed with PBS then incubated
117 with goat anti-mouse FITC secondary antibody at a dilution ratio of 1/50 for 45 minutes at room
118 temperature in the dark. Finally, 4',6-diamidino-2-phenylindole (DAPI) was applied on the washed
119 cells and examined under fluorescence microscope. During the evaluation, positivity in the cells
120 in the whole field was evaluated semi-quantitatively as follows; absent (-), mild (+), moderate (++)
121 and severe (+++).

122 **Statistical analysis**

123 The results were stated as a mean \pm standard error of the mean (SEM). Statistical evaluation of the
124 data was done with SPSS Version 23.0 for Windows using One Way ANOVA and a postdoc Tukey
125 test. The results obtained from BCL-2, cleaved caspase 3, BAX, cleaved PARP and 8-oxo-dG
126 levels tests were examined using Independent Samples t Test. For anti-gamma H2AX and anti-
127 Cytochrome C staining statistical evaluation of the data was performed by One Way ANOVA.
128 Differences were evaluated statistically significant at *: $P < 0.05$, **: $P < 0.01$ and ***: $P < 0.001$.
129 GraphPad Prism 8.0 software (USA) was used for data analysis and graphical presentations.

130 **Results**

131 *Cytotoxic effect of sinapic acid on HT-29 cells*

132 The cytotoxic effect of sinapic acid was assessed in HT-29 cells. At 200 μM and higher doses,
133 sinapic acid significantly inhibited the growth of HT-29 cells as compared to control ($P < 0.05$).
134 The IC50 value of sinapic acid in HT-29 cells was found to be 317.5 μM for 24 hours (Figure 2).

135 ***The effect of sinapic acid on BCL-2, cleaved caspase 3, BAX, and cleaved PARP levels in HT-***
136 ***29 cells***

137 ELISA was used to evaluate the expression of apoptosis-related proteins in HT-29 cells, such as
138 BCL-2, cleaved caspase 3, BAX, and cleaved PARP. The treatment with sinapic acid (317.5 μM)
139 for 24 hours significantly increased cleaved caspase 3, BAX, and cleaved PARP levels ($p < 0.05$).
140 In contrast, sinapic acid had no effect on BCL-2 level ($p > 0.05$) (Fig. 3).

141 ***Effect of sinapic acid on 8-oxo-dG level in HT-29 cells***

142 ELISA was used to assess 8-oxo-dG expression in HT-29 cells in order to determine the DNA-
143 damaging effects of sinapic acid. Treatment with sinapic acid (317.5 μM) for 24 hours significantly
144 elevated the quantity of 8-oxo-dG ($p < 0.01$) (Fig. 4)

145 ***Effect of sinapic acid on γ -H2AX and cytochrome-C levels in HT-29 cells***

146 We stained 6 samples from both the experimental and control groups. The differences in gamma-
147 H2AX foci and cytochrome-C quantities were statistically significant ($p < 0.05$) (Table 1). It is
148 obviously that the levels of cytochrome-C in microscope field of view 40x are lower and the levels
149 of γ -H2AX foci are higher in the experimental samples compared with the control samples (Figure
150 5).

151 **Discussion**

152 Despite considerable progress achieved in the areas of cancer diagnosis and treatment, cancer is
153 still one of the leading causes of death worldwide. In 2022, it is estimated that 52,580 of the total
154 609,360 cancer deaths in the United States will be caused by colorectal cancer, becoming the
155 second cause of cancer death after lung cancer (29). Novel treatments for cancer often fail owing
156 to frequent genetic changes and mutations in cancer genes. Because of the frequent side effects
157 caused by chemotherapy, we still in need to new, more effective and safer treatments for metastatic
158 cancers. There is increasing interest in developing drugs from various natural sources including
159 plants, animals, and microorganisms to overcome these problems (30). Natural products have been
160 in use as traditional medicines to treat different sorts of diseases including cancer all over the world
161 for thousands of years. Several studies have detected a wide spectrum of biological activities of
162 natural products such as, stimulation of the immune system, antimicrobial, anti-hepatotoxic, anti-
163 ulcer, antioxidant, anti-inflammatory, anti-mutagenic, and anti-cancer effects (31). Sinapic acid
164 and its derivatives have been suggested for potential use in food processing, cosmetics, and the
165 pharmaceutical industries due to their antioxidative activity (23). Several studies have
166 demonstrated its anti-cancer activity, Abdel Naser et al. (2020) indicated the cytotoxic effect on
167 Human squamous cell carcinoma cell line (HEp-2) and found that the intracellular reactive oxygen
168 species (ROS) levels were increased in sinapic acid and nano-sinapic acid treated cells as compared
169 to the untreated cells (32). The antiproliferative, apoptotic and anti-invasive effects of SA on PC-
170 3 (Androgen Independent Phenotype) and LNCaP (Androgen Dependent Phenotype) prostate cell
171 lines were determined by Eroğlu M et al. (2018) (33). Hudson EA et al. (2000) demonstrated the
172 inhibiting effect of SA on the clonogenicity of human-derived colon carcinoma cell lines (SW 480)
173 (34). Sinapic acid inhibited the growth of cervical cancer (HeLa) and colon cancer (HT29) cell
174 lines more effectively than the well-known histone deacetylase inhibitor, sodium butyrate. These

175 antiproliferative effects were mediated by induction of apoptosis (35). The cytotoxic effect of
176 sinapic acid on Human laryngeal carcinoma cell line (HEp-2) was confirmed by Janakiraman K et
177 al. (2015). This effect was the result of promoting apoptosis accompanied by loss of cell viability,
178 increasing ROS levels and cell cycle arrest by the induction of G0/G1 phase arrest (36). Xinglong
179 Hu et al. (2021) determined the anti-cancer activity of SA against lung cancer both in-vitro and in-
180 vivo. The administration of SA was showed to ameliorate the exposure of B[a]P mediated lung
181 cancer in swiss albino mice by a decrease in IgG and IgM level, leukocyte count, neutrophil
182 function tests, soluble immune complex, lipid peroxidation, pro-inflammatory cytokines, tumor
183 markers and increased phagocytic index, activity index and antioxidant defense enzymes. Besides,
184 in-vitro studies exhibited a potential cytotoxic and apoptotic activity by increasing ROS production
185 and caspase activity (caspase-3 and caspase-9) in human lung cancer cell lines (A549) (37). Both
186 free SA and *Leucaena leucocephala* galactomannan (LLG) conjugated SA were found to have
187 similar antiproliferative activity against human colon cancer cell lines (HCT-116 cells) according
188 to a study conducted by Jasleen Kaur et al. (2021) (38). Antiproliferative and histone deacetylase
189 inhibitory activity of peanut phenolics including ferulic acid, p-Coumaric acid and sinapic acid
190 were assessed in MCF-7 breast cancer and HeLa cervical cancer cells. All the compounds were
191 found to have antiproliferative, apoptotic and histone deacetylase inhibitory effects in both cell
192 lines. Furthermore, all of the compounds led to cell cycle arrest at G0/G1 phase in MCF-7 cells
193 and S-phase arrest in HeLa cells induced by p-Coumaric acid and ferulic acid (39). A study
194 conducted by Huang Z et al (2021) demonstrated that SA inhibited growth, migration, and invasion
195 of pancreatic cancer cells. Both the in vitro (PC cell lines PANC-1 and SW1990) and in vivo (mice
196 injected with SW1990 cells) models indicated the anticancer activities of SA without inducing
197 apoptosis. These results were associated with downregulation of the AKT/Gsk-3 β signal pathway

198 which has been shown to play a pivotal role in inhibiting apoptosis and cancer development (40).
199 The anti-cancer activity of free and encapsulated sinapic acid was also determined against lung
200 (A549), and colon (CaCo2) cancer cell lines along with up regulation of P53 and BAX and a down
201 regulation of BCL-2 genes in both cell lines (41).

202 The present study aimed to evaluate the cytotoxic and apoptotic effect of sinapic acid on colon
203 cancer HT-29 cell lines. Our findings showed that sinapic acid had a concentration-dependent
204 cytotoxic effect on HT-29 cells. It significantly inhibited HT-29 cell proliferation in a
205 concentration-dependent manner, with an IC₅₀ value of 317.5 μ M after 24 hours.

206 One approach for treating cancer is to obtain control or stop the uncontrolled growth of cancer
207 cells. Recruiting the cell's own mechanism for death is a very effective anti-cancer method. Since
208 apoptosis evasion is a hallmark regardless of the cause or type of the cancer, inducing apoptosis is
209 one of the most successful non-surgical treatments. This induction can be achieved by either
210 stimulation of pro-apoptotic proteins or inhibition of anti-apoptotic proteins (42).

211 The levels of BCL-2, cleaved caspase 3, BAX, and cleaved PARP were measured using ELISA
212 technique to investigate the apoptotic effect of sinapic acid on HT-29 cells. The intrinsic pathway
213 of apoptosis is regulated by the BCL-2 protein family (43). Different apoptotic stimulants lead to
214 the upregulation of BH3-only proteins, which activate both BAX and BAK (44). BAX and BAK
215 then oligomerize and lead to the permeabilization of mitochondrial outer membrane which
216 represents the decisive event of intrinsic pathway (45). The permeabilization results in the release
217 of intermembrane proteins like cytochrome c which contributes with apoptotic protease-activating
218 factor-1 (APAF-1), dATP and procaspase-9 to the formation of apoptosome (46). This leads to the
219 conversion of procaspase-9 into caspase-9 within the apoptosome (43) The caspase-9 in turn
220 activates the executioner (caspase-3 and -7) (47). Executioner caspases cleave target proteins

221 resulting in cell apoptotic breakdown. Caspase-3 and -7 are responsible for the proteolytic cleavage
222 of poly (ADP-ribose) polymerase-1 (PARP-1), an ADP-ribosylating enzyme essential for
223 initiating various cellular processes, including DNA repair, regulation of chromatin structure,
224 transcription, replication and recombination. The cleavage of PARP-1 thus prevents the
225 recruitment of the enzyme to DNA damage sites (48). In the present study, 317.5 μ M sinapic acid
226 treatment significantly elevated pro-apoptotic Bax, cleaved caspase 3, and cleaved PARP protein
227 expressions ($p < 0.05$), while not altering anti-apoptotic BCL-2 expression ($p > 0.05$). These results
228 confirm the apoptotic effect of sinapic acid on HT-29 cells. Besides, the immunofluorescence
229 staining of cytochrome-c showed that the number of cells with intact mitochondria is significantly
230 lower in the experimental group compared to the control group as they released more cytochrome-c
231 during apoptosis induced by sinapic acid.

232 In nuclear and mitochondrial DNA, 8-oxo-dG is a prevalent free-radical-induced oxidative lesion.
233 Thus 8-oxo-dG has been commonly used in many studies as a biomarker to measure endogenous
234 oxidative DNA damage, and as a risk factor for many diseases including cancer, because urinary
235 8-oxo-dG is a good biomarker to estimate the risk of different cancers and other degenerative
236 diseases (49). Increasing the ROS level over the cytotoxic threshold can selectively kill cancer
237 cells. The increased ROS level disrupts the cellular reduction-oxidation (redox) homeostasis and
238 as a result leads to the death of cancer cells. If exogenous ROS-generating agents are triggered,
239 the redox-imbalanced cancer cells become more susceptible than normal cells, thereby resulting
240 in cell death (50). The 8-oxo-dG ELISA kit was used in our study to investigate DNA
241 fragmentation in HT-29 cells after 24 hours of sinapic acid treatment. The results indicate the
242 cytotoxic activity of sinapic acid is associated with oxidative DNA damage. γ -H2AX is a
243 phosphorylated form of the histone, H2AX. This phosphorylation follows the formation of DNA

244 double strand breaks as a result of DNA damage (51). According to the results of our
245 immunofluorescence staining of γ -H2AX, there was a significant increase in γ -H2AX levels which
246 assures the occurrence of DNA damage as a possible mechanism of the anticancer activity of
247 sinapic acid.

248 **Conclusion**

249 Sinapic acid significantly suppressed HT-29 cell growth in a concentration-dependent way.
250 Sinapic acid treatment significantly elevated pro-apoptotic cleaved caspase 3, BAX, and cleaved
251 PARP levels as well as mitochondrial cytochrome-c release. Sinapic acid treatment also
252 significantly elevated 8-oxo-dG quantities in HT-29 cells and thus the cytotoxic effect of sinapic
253 acid may be linked to oxidative DNA damage. Therefore, the present study suggests that sinapic
254 acid has the potential to be a promising therapeutic agent for colon cancer. However, these findings
255 need to be supported by in vivo and clinical studies.

256 **Address for correspondence:** Levent HACISULEYMAN, Sivas Cumhuriyet University, School
257 of Pharmacy, Department of Pharmacology, Sivas, Turkey.

258 **Competing Interests:** The authors declare there are no competing interests.

259 **Funding:** The authors declare no specific funding for this work.

260 **Data availability:** Data generated or analyzed during this study are available from the
261 corresponding author upon reasonable request.

262 **References**

- 263 1. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality,
264 survival, and risk factors. *Prz Gastroenterol.* 2019;14(2):89-103. doi:
265 10.5114/pg.2018.81072. Epub 2019 Jan 6. PMID: 31616522; PMCID: PMC6791134.

- 266 2. Jamal A, Siegel R, Ward E, et al. Cancer statistics, 2007. *CA Cancer J Clin* 2007;57: 43–
267 66.
- 268 3. Hassan C, Zullo A, Laghi A, et al. Colon cancer prevention in Italy: cost-effectiveness
269 analysis with CT colonography and endoscopy. *Dig Liver Dis* 2007;39:242–50.
- 270 4. Shibuya K, Mathers CD, Boschi-Pinto C, et al. Global and regional estimates of cancer
271 mortality and incidence by site: II. Results for the global burden of disease 2000. *BMC*
272 *Cancer* 2002;2:37.
- 273 5. Endo H, Hosono K, Fujisawa T, et al. Involvement of JNK pathway in the promotion of
274 the early stage of colorectal carcinogenesis under high-fat dietary conditions. *Gut* 2009;
275 58(12): 1637–1643
- 276 6. Nakaji S, Umeda T, Shimoyama T, et al. Environmental factors affect colon carcinoma
277 and rectal carcinoma in men and women differently. *International Journal of Colorectal*
278 *Disease* 2003;18:481–6.
- 279 7. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the
280 evidence. *The Journal of Nutrition* 2001;131:3109S–20S.
- 281 8. Merritt AJ, Potten CS, Kemp CJ, et al. The role of p53 in spontaneous and radiation-
282 induced apoptosis in the gastrointestinal tract of normal and p53- deficient mice. *Cancer*
283 *Res* 1994;54:614–17.
- 284 9. Merritt AJ, Potten CS, Watson AJM, et al. Differential expression of Bcl-2 in intestinal
285 epithelia—correlation with attenuation of apoptosis in colonic crypts and the incidence of
286 colonic neoplasia. *J Cell Sci* 1995;108(Pt 6):2261–71.

- 287 10. Pritchard DM, Potten CS, Korsmeyer SJ, et al. Damage-induced apoptosis in intestinal
288 epithelia from bcl-2-null and bax-null mice: Investigations of the mechanistic
289 determinants of epithelial apoptosis in vivo. *Oncogene* 1999;18:7287–93.
- 290 11. Pritchard DM, Print C, O'Reilly L, et al. Bcl-w is an important determinant of damage-
291 induced apoptosis in epithelia of small and large intestine. *Oncogene* 2000;19(34):3955–
292 9.
- 293 12. Johnson IT. Anticarcinogenic effects of diet-related apoptosis in the colorectal mucosa.
294 *Food Chem Toxicol* 2002;40:1171–8.
- 295 13. Bartsch H, Nair J and Owen RW. Exocyclic DNA adducts as oxidative stress markers in
296 colon carcinogenesis: potential role of lipid peroxidation, dietary fat and antioxidants.
297 *Biol Chem* 2002; 383(6): 915–921.
- 298 14. Martínez-Maqueda, D; et al. (2015). "HT29 Cell Line". *The Impact of Food Bioactives*
299 *on Health*. Springer. pp. 113–124. doi:10.1007/978-3-319-16104-4_11. ISBN 978-3-319-
300 15791 7. PMID 29787047.
- 301 15. Coudray, Anne-Marie; et al. (1 December 1989). "Proliferation of the Human Colon
302 Carcinoma Cell Line HT29: Autocrine Growth and Deregulated Expression of the c-myc
303 Oncogene" (PDF). *Cancer Research*. 49 (23): 6566–6571. PMID 2684395.
- 304 16. Mishra J, Drummond J, Quazi SH, Karanki SS, Shaw JJ, Chen B, Kumar N. Prospective
305 of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell
306 apoptosis. *Crit Rev Oncol Hematol*. 2013 Jun;86(3):232-50. doi:
307 10.1016/j.critrevonc.2012.09.014. Epub 2012 Oct 23. PMID: 23098684; PMCID:
308 PMC3561496.

- 309 17. Ekor M (2014) The growing use of herbal medicines: issues relating to adverse reactions
310 and challenges in monitoring safety. *Front Pharmacol* 4:177.
- 311 18. S.A. Heleno, A. Martins, M.J.R.P. Queiroz, I.C.F.R. Ferreira, *Food Chem.* 173 (2015)
312 501–513.
- 313 19. K.L. Tuck, P.J. Hayball, *J. Nutr. Biochem.* 13 (2002) 636–644.
- 314 20. H.R. El-Seedi, A.M. El-Said, S.A. Khalifa, U. Goransson, L. Bohlin, A.K. Borg-Karlson,
315 R. Verpoorte, Biosynthesis, natural sources, dietary intake, pharmacokinetic properties,
316 and biological activities of hydroxycinnamic acids, *J. Agric. Food Chem.* 60 (2012)
317 10877–10895.
- 318 21. Hosny H, El Gohary N, Saad E, Handoussa H, El Nashar RM (2018) Isolation of sinapic
319 acid from broccoli using molecularly imprinted polymers. *J Sep Sci* 41(5):1164–1172.
- 320 22. Menezes JC, Kamat SP, Cavaleiro JA, Gaspar A, Garrido J, Borges F (2011) Synthesis
321 and antioxidant activity of long chain alkyl hydroxycinnamates. *Eur J Med Chem*
322 46(2):773–777.
- 323 23. Nićiforović N, Abramović H, Sinapic acid and its derivatives: Natural sources and
324 bioactivity, *Compr Rev Food Sci Food Safety* 13(1), 34–51, 2014.
325 <http://dx.doi.org/10.1111/1541-4337.12041>.
- 326 24. Lee-Manion AM, Price RK, Strain JJ, Dimberg LH, Sunnerheim K, Welch RW (2009) In
327 vitro antioxidant activity and antigenotoxic effects of avenanthramides and related
328 compounds. *J Agric Food Chem* 57(22):10619–106224.
- 329 25. Cos P, Rajan P, Vedernikova I, Calomme M, Pieters L, Vlietinck AJ, Augustyns K,
330 Haemers A, Vanden Berghe D (2002) In vitro antioxidant profile of phenolic acid
331 derivatives. *Free Radic Res* 36(6):711–716.

- 332 26. Cartea M.E., Francisco M., Soengas P., Velasco P., Phenolic compounds in Brassica
333 vegetables, *Molecules*, 2010, 16(1), 251-280.
- 334 27. Chen C. Sinapic acid and its derivatives as medicine in oxidative stress-induced diseases
335 and aging, *Oxid Med Cell Longev*, 2016, 2016, 3571614.
- 336 28. Ergul M, Bakar-Ates F. Investigation of molecular mechanisms underlying the
337 antiproliferative effects of colchicine against PC3 prostate cancer cells. *Toxicol Vitro*
338 2021; 73. <https://doi.org/10.1016/j.tiv.2021.105138>.
- 339 29. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin*.
340 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12. PMID: 35020204.
- 341 30. Thazin Nwe Aung, Zhipeng Qu, R. Daniel Kortschak and David L. Adelson.
342 Understanding the Effectiveness of Natural Compound Mixtures in Cancer through Their
343 Molecular Mode of Action; *Int. J. Mol. Sci.* 2017; 18 (3): 656. Doi:
344 10.3390/ijms18030656.
- 345 31. Rajamanickam S, Agarwal R. Natural products and colon cancer: current status and
346 future prospects. *Drug Dev Res.* 2008 Nov 1;69(7):460-471. doi: 10.1002/ddr.20276.
347 PMID: 19884979; PMCID: PMC2659299.
- 348 32. Abdel Naser, Gehan & Elazab, Samia & Elbolok, Amr & Elgayar, Sherif & Mohamed,
349 Aly. (2020). Antioxidant and Apoptotic Activity of Free and Nano-Sinapic Acid on HEP-
350 2 Cell Line. *Indian Journal of Public Health Research and Development.* 11. 953-958.
351 10.37506/ijphrd.v11i4.7790.
- 352 33. Eroğlu C, Avcı E, Vural H, Kurar E. Anticancer mechanism of Sinapic acid in PC-3 and
353 LNCaP human prostate cancer cell lines. *Gene.* 2018 Sep 10;671:127-134. doi:
354 10.1016/j.gene.2018.05.049. Epub 2018 May 22. PMID: 29792952.

- 355 34. Hudson EA, Dinh PA, Kokubun T, Simmonds MS, Gescher A. Characterization of
356 potentially chemopreventive phenols in extracts of brown rice that inhibit the
357 growth of human breast and colon cancer cells. *Cancer Epidemiol Biomarkers*
358 *Prev.* 2000 Nov;9(11):1163-70. PMID: 11097223.
- 359 35. Senawong T, Misuna S, Khaopha S, Nuchadomrong S, Sawatsitang P, Phaosiri C,
360 Surapaitoon A, Sripa B. Histone deacetylase (HDAC) inhibitory and antiproliferative
361 activities of phenolic-rich extracts derived from the rhizome of *Hydnophytum*
362 *formicarum* Jack.: sinapinic acid acts as HDAC inhibitor. *BMC Complement Altern Med.*
363 2013 Sep 22;13:232. doi: 10.1186/1472-6882-13-232. PMID: 24053181; PMCID:
364 PMC3848914.
- 365 36. Janakiraman, K., Kathiresan, S., & Mariadoss, A.V. (2015). INFLUENCE OF SINAPIC ACID ON
366 INDUCTION OF APOPTOSIS IN HUMAN LARYNGEAL CARCINOMA CELL LINE.
- 367 37. Xinglong Hu, Royapuram Veeraragavan Geetha, Krishna Mohan Surapaneni, Vishnu
368 Priya Veeraraghavan, Arunachalam Chinnathambi, Tahani Awad Alahmadi, Velu
369 Manikandan, Kalaivani Manokaran. Lung cancer induced by Benzo(A)Pyrene:
370 ChemoProtective effect of sinapic acid in swiss albino mice, *Saudi Journal of Biological*
371 *Sciences*, Volume 28, Issue 12, 2021, 7125-7133, ISSN 1319-562X.
372 <https://doi.org/10.1016/j.sjbs.2021.08.001>
- 373 38. Jasleen Kaur, Vikrant Mehta, Gurpreet Kaur, Preparation, development and
374 characterization of *Leucaena leucocephala* galactomannan (LLG) conjugated sinapic
375 acid: A potential colon targeted prodrug, *International Journal of Biological*
376 *Macromolecules*, Volume 178, 2021, 29-40, ISSN 0141-8130,
377 <https://doi.org/10.1016/j.ijbiomac.2021.02.132>.

- 378 39. Saenglee, S.; Jogloy, S.; Patanothai, A.; Leid, M.; Senawong, T. Cytotoxic effects of
379 peanut phenolics possessing histone deacetylase inhibitory activity in breast and cervical
380 cancer cell lines. *Pharmacol. Rep.* 2016, 68, 1102–1110.
- 381 40. Huang Z, Chen H, Tan P, Huang M, Shi H, Sun B, Cheng Y, Li T, Mou Z, Li Q, Fu W.
382 Sinapic acid inhibits pancreatic cancer proliferation, migration, and invasion via
383 downregulation of the AKT/Gsk-3 β signal pathway. *Drug Dev Res.* 2022
384 May;83(3):721-734. doi: 10.1002/ddr.21904. Epub 2021 Dec 3. PMID: 34859906.
- 385 41. Badr, D.A., Amer, M.E., Abd-Elhay, W.M. et al. Histopathological and genetic changes
386 proved the anti-cancer potential of free and nano-capsulated sinapic acid. *Appl Biol*
387 *Chem* 62, 59 (2019). <https://doi.org/10.1186/s13765-019-0462-0>.
- 388 42. Pfeffer CM, Singh ATK. Apoptosis: A Target for Anticancer Therapy. *Int J Mol Sci.*
389 2018 Feb 2;19(2):448. doi: 10.3390/ijms19020448. PMID: 29393886; PMCID:
390 PMC5855670.
- 391 43. Zaman S., Wang R., Gandhi V. Targeting the apoptosis pathway in hematologic
392 malignancies. *Leuk. Lymphoma.* 2014;55:1980–1992. doi:
393 10.3109/10428194.2013.855307.
- 394 44. Lomonosova E., Chinnadurai G. BH3-only proteins in apoptosis and beyond: An
395 overview. *Oncogene.* 2008;27:S2–S19. doi: 10.1038/onc.2009.39.
- 396 45. Lopez J., Tait S.W.G. Mitochondrial apoptosis: Killing cancer using the enemy within.
397 *Br. J. Cancer.* 2015;112:957–962. doi: 10.1038/bjc.2015.85.
- 398 46. Hassan M., Watari H., AbuAlmaaty A., Ohba Y., Sakuragi N. Apoptosis and molecular
399 targeting therapy in cancer. *BioMed Res. Int.* 2014;2014 doi: 10.1155/2014/150845.

- 400 47. Green D.R., Llambi F. Cell death signaling. Cold Spring Harb. Perspect. Biol.
401 2015;7:a006080. doi: 10.1101/cshperspect.a006080.
- 402 48. Los M, Mozoluk M, Ferrari D, Stepczynska A, Stroh C, Renz A, Herceg Z, Wang ZQ,
403 Schulze-Osthoff K. Activation and caspase-mediated inhibition of PARP: a molecular
404 switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol Biol
405 Cell. 2002 Mar;13(3):978-88. doi: 10.1091/mbc.01-05-0272. PMID: 11907276; PMCID:
406 PMC99613.
- 407 49. Ock CY, Kim EH, Choi DJ, Lee HJ, Hahm KB, Chung MH. 8-Hydroxydeoxyguanosine:
408 not mere biomarker for oxidative stress, but remedy for oxidative stress-implicated
409 gastrointestinal diseases. World J Gastroenterol. 2012 Jan 28;18(4):302-8. doi:
410 10.3748/wjg.v18.i4.302. PMID: 22294836; PMCID: PMC3261525.
- 411 50. Kim SJ, Kim HS, Seo YR. Understanding of ROS-Inducing Strategy in Anticancer
412 Therapy. Oxid Med Cell Longev. 2019 Dec 18;2019:5381692. doi:
413 10.1155/2019/5381692. PMID: 31929855; PMCID: PMC6939418.
- 414 51. Kuo LJ, Yang LX. Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In
415 Vivo. 2008 May-Jun;22(3):305-9. PMID: 18610740.

Table 1		
Samples	Gamma-H2AX	Cytochrome-C
Control sample-1	+	+++
Control sample-2	++	+++
Control sample-3	+	++
Control sample-4	+	+++
Control sample-5	+	++
Control sample-6	+	+++
Experimental sample-1	+++	+
Experimental sample-2	++	+
Experimental sample-3	+++	+
Experimental sample-4	+++	+
Experimental sample-5	+++	-
Experimental sample-6	+++	+
Mean values \pm standard deviation		
Control group	1.16 \pm 0.40	2.66 \pm 0.51
Experimental group	2.83 \pm 0.40	0.83 \pm 0.40





Fig. 1 Structure of Sinapic acid


Structure of Sinapic Acid

187x136mm (96 x 96 DPI)



The antiproliferative effects of sinapic acid on HT-29 cells. The findings are evaluated as a percentage of viable cells versus control. The results are presented as the mean \pm SEM of three samples. *: $P < 0.05$ and ***: $P < 0.001$ as compared to the control group.


107x83mm (300 x 300 DPI)



Sinapic acid (317.5 μ M) enhanced apoptosis of HT-29 cells. The BCL-2, cleaved caspase 3, BAX and cleaved PARP levels were assessed using the ELISA kits. Results are represented as mean \pm SEM of three samples.

*: P < 0.05 as compared to the control group

261x190mm (300 x 300 DPI)



Sinapic acid (317.5 μM) enhanced DNA damage of HT-29 cells. The 8-oxo-dG level was assessed using the ELISA kit. Results are represented as mean ± SEM of three samples. **: P < 0.01 as compared to the control group

105x68mm (300 x 300 DPI)




Fig 5: Gamma-H2AX expression was significantly higher in the experimental group B compared to the control group A ($P < 0.05$), while cytochrome-C expression was significantly lower in the experimental group D compared to the control group C ($P < 0.05$) $\times 40$.

515x413mm (96 x 96 DPI)